Target: CD20.
Clone: 2H7.
Specificity: Anti-CD20 In Vivo Antibody - Ultra Low Endotoxin (2H7) recognizes an epitope on Human CD20.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: The CD20 antigen, also called MS4A1, B1 and Bp35, is a non-glycosylated, transmembrane spanning, phosphoprotein. The CD20 protein is present on human pre B lymphocytes and on B lymphocytes at all stages of maturation, except on plasma cells, and is synchronous with the expression of surface IgM. It is also expressed in some follicular dendritic cells and at low levels on a T cell subset. CD20 has been shown to be heavily phosphorylated in activated B cells and malignant B cells. Homo-oligomeric complexes of CD20 are thought to form Ca2+ conductive ion channels in the plasma membrane of B cells. The CD20 molecule is involved in B cell activation and is associated with various Src family kinases (Lyn, Lck, Fyn), and exists in a complex with MHC class I and II, CD53, CD81, and CD82. Extensive CD20 cross-linking may also influence cell death by apoptosis. Therapy with antibodies against CD20 is a widely used regimen in the treatment of all B cell lymphomas and leukemias.
Concentration: 1.0 - 5.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
